Qubigen to Attend JPM Week 2026 in San Francisco, Engaging Investors & Exploring Strategic Partnerships

Qubigen is pleased to announce its participation at JPM Week 2026 in San Francisco, the premier global gathering for biotech, pharma, medtech, and life sciences investment. JPM Week sees hundreds of industry leaders, investors, innovators and entrepreneurs convene each January in San Francisco, offering a unique moment to build partnerships, explore business development and invest in the future of healthcare innovation.

 

Qubigen Attendees

Representing Qubigen at JPM Week will be key members of our leadership, governance and advisory teams:

• Dr. Jonathan Hall, Co-Founder & CEO

• Dr. Sonya Diakiw, Co-Founder & CSO

• Amir Zalcenstein, Board Member

• Michelle Perrugini, Board Member

• Eric Hayes, Qubigen Consulting Team (Pullan Consulting)

• Linda Pullan Qubigen Consulting Team (Pullan Consulting)

• Trevor Thompson, Qubigen Fundraising Advisor

Qubigen is committed to forming meaningful connections, from scientific partners and drug design collaborators, to investors and strategic stakeholders.

 

JPM Week Objectives

JPM Week has evolved far beyond a single conference, it is now the heartbeat of global biotech and pharma investment and partnering. For Qubigen, it represents an unparalleled opportunity to engage with investors who share its vision for AI enabled, data secure drug design, and to explore business development and partnership opportunities across pharmaceutical, biotech, and research institutions. It also provides an important moment to strengthen relationships with existing stakeholders as Qubigen enters its next phase of growth.

Through its presence at JPM Week, Qubigen aims to spark collaborations around challenging therapeutic targets, data-revival initiatives, and novel discovery programs, to accelerate the delivery of next-generation precision therapeutics: faster, smarter, and securely, without exposing sensitive data or intellectual property. Qubigen will showcase its unique offering, FedAIDD - a secure Federated AI Drug Design platform enhanced by quantum chemistry driven molecular design capabilities.

Connect With Qubigen via the Bio Partnering App

To facilitate partner and investor meetings during the week, Qubigen will be available on the Bio Partnering App.  Qubigen welcomes meeting requests from biopharma companies, investors, research institutes, and collaborators interested in learning more about how FedAIDD and virtual screening capabilities can support their drug development programs. If you’re attending JPM Week, we encourage you to reach out to arrange a chat.

Qubigen: accelerate drug design without exposing secrets

Whether you're advancing active programs, reviving dormant data, or starting from scratch, Qubigen’s secure AI platform and virtual screening capabilities can help you identify, optimize, and accelerate the path to promising lead drug candidates. Get in touch to explore how we can support your next development.

enquiries@qubigen.com